NorthWest Biotherapeutics Inc (NWBO)

[KRISGO]

From ChatGPT:

🧠 Patient’s Current Situation
Tumor is unresectable: Surgery is not an option.
Standard of care: Radiation + temozolomide (TMZ).
Average prognosis: 11–14 months if only standard therapy is used.
Motivation: Wants to go beyond just “standard care” because of limited survival time.

🌟 Patient’s Hope / Goal
They are looking toward personalized immunotherapy, which is not yet widely available.
The key is to stay healthy and control tumor progression long enough for this therapy to be ready and administered.
They understand that immunotherapy could potentially become a “new standard of care” in the future.

💡 What They Might Be Considering
Based on current immunotherapy developments for brain cancer (especially glioblastoma):
1. DCVax-L / Dendritic cell vaccines
Personalized vaccines made from the patient’s own tumor cells.
Aim: Train the immune system to recognize and attack the tumor.
Clinical trials are ongoing; may fit exactly what the patient hopes for.

2. Checkpoint inhibitors (e.g., anti-PD-1 / anti-PD-L1 drugs)
Usually more effective in cancers with high mutation loads; limited success in brain tumors so far.
May be part of future combination therapies.

3. CAR-T or T-cell therapies
Genetically modified immune cells targeting tumor-specific antigens.
Experimental in glioblastoma; could be available in trials in the next few years.

4. Other personalized or combination immunotherapies
Could include peptide vaccines, oncolytic viruses, or immune-stimulating therapies.
The patient likely hopes to bridge current standard therapy to one of these experimental options.